SNY — Sanofi SA Income Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeLarge CapNeutral

Annual income statement for Sanofi SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.

	R2020 December 31st	2021 December 31st	2022 December 31st	R2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	37,369	39,175	45,389	41,618	44,286
Cost of Revenue
Gross Profit	25,210	26,920	31,694	28,990	31,081
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	23,256	31,049	34,733	34,658	37,034
Operating Profit	14,113	8,126	10,656	6,960	7,252
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	13,778	7,798	10,422	6,251	6,698
Provision for Income Taxes
Net Income After Taxes	11,971	6,240	8,416	5,234	5,494
Minority Interest
Equity in Affiliates
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	12,294	6,223	8,371	5,400	5,560
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	12,294	6,223	8,371	5,400	5,560
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	10.3	5.1	5.8	5.1	5.33
Dividends per Share